A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic
Gespeichert in:
| Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2021-03, Vol.35 (3), p.e169-e170 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e170 |
|---|---|
| container_issue | 3 |
| container_start_page | e169 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 35 |
| creator | Hansel, K. Zangrilli, A. Bianchi, L. Peris, K. Chiricozzi, A. Offidani, A. Diotallevi, F. Fargnoli, M.C. Esposito, M. Amerio, P. Gualdi, G. Bianchi, L. Stingeni, L. |
| description | |
| doi_str_mv | 10.1111/jdv.17003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2452983210</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2452983210</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-97aa06e21b495cc76aa31223320ee572988dc027622d3225b0427a813675909f3</originalsourceid><addsrcrecordid>eNp1kUtOwzAQhi0EoqWw4ALIS1ik9aN5mF1VXkWVuoFuI9eZgEviBDuhlBVHYMn5OAmGAjtmMyPNp2-k-RE6pKRPfQ2W2VOfxoTwLdSlwygJOEn4NuoSwaJAiFB00J5zS0IIpWGyizrcA35mXfQ-wmVbNFqBacBi17TZGlcGQ56DavQTGHAOS5NhJ3No_C7HVjtpHvRLW8oF1gbXrrJaOu1OPYgnjSy07zT6eH1bATxgC7Lwc6FzwPBcg9VgFOCstdrc4eYe8Hg2n5x5hApc-1tQarWPdnJZODj46T10e3F-M74KprPLyXg0DRRPEh6IWEoSAaOLoQiViiMpOWWMc0YAwpiJJMkUYXHEWMYZCxdkyGKZUB7FoSAi5z10vPHWtnpswTVpqZ2CopAGqtalbBh6CWeUePRkgypbOWchT2urS2nXKSXpVxCpDyL9DsKzRz_adlFC9kf-ft4Dgw2w0gWs_zel12fzjfIT7ZmUsw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452983210</pqid></control><display><type>article</type><title>A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hansel, K. ; Zangrilli, A. ; Bianchi, L. ; Peris, K. ; Chiricozzi, A. ; Offidani, A. ; Diotallevi, F. ; Fargnoli, M.C. ; Esposito, M. ; Amerio, P. ; Gualdi, G. ; Bianchi, L. ; Stingeni, L.</creator><creatorcontrib>Hansel, K. ; Zangrilli, A. ; Bianchi, L. ; Peris, K. ; Chiricozzi, A. ; Offidani, A. ; Diotallevi, F. ; Fargnoli, M.C. ; Esposito, M. ; Amerio, P. ; Gualdi, G. ; Bianchi, L. ; Stingeni, L.</creatorcontrib><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.17003</identifier><identifier>PMID: 33080112</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - therapeutic use ; COVID-19 - epidemiology ; Female ; Humans ; Italy - epidemiology ; Male ; Middle Aged ; Pandemics ; Psoriasis - drug therapy ; SARS-CoV-2</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2021-03, Vol.35 (3), p.e169-e170</ispartof><rights>2020 European Academy of Dermatology and Venereology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-97aa06e21b495cc76aa31223320ee572988dc027622d3225b0427a813675909f3</citedby><cites>FETCH-LOGICAL-c3883-97aa06e21b495cc76aa31223320ee572988dc027622d3225b0427a813675909f3</cites><orcidid>0000-0001-7919-8141 ; 0000-0002-4773-6993 ; 0000-0002-6674-4278 ; 0000-0002-7249-2556 ; 0000-0003-2274-1742 ; 0000-0003-1957-6600 ; 0000-0002-1640-6609 ; 0000-0002-6739-0387</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjdv.17003$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjdv.17003$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33080112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hansel, K.</creatorcontrib><creatorcontrib>Zangrilli, A.</creatorcontrib><creatorcontrib>Bianchi, L.</creatorcontrib><creatorcontrib>Peris, K.</creatorcontrib><creatorcontrib>Chiricozzi, A.</creatorcontrib><creatorcontrib>Offidani, A.</creatorcontrib><creatorcontrib>Diotallevi, F.</creatorcontrib><creatorcontrib>Fargnoli, M.C.</creatorcontrib><creatorcontrib>Esposito, M.</creatorcontrib><creatorcontrib>Amerio, P.</creatorcontrib><creatorcontrib>Gualdi, G.</creatorcontrib><creatorcontrib>Bianchi, L.</creatorcontrib><creatorcontrib>Stingeni, L.</creatorcontrib><title>A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>COVID-19 - epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Italy - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>Psoriasis - drug therapy</subject><subject>SARS-CoV-2</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtOwzAQhi0EoqWw4ALIS1ik9aN5mF1VXkWVuoFuI9eZgEviBDuhlBVHYMn5OAmGAjtmMyPNp2-k-RE6pKRPfQ2W2VOfxoTwLdSlwygJOEn4NuoSwaJAiFB00J5zS0IIpWGyizrcA35mXfQ-wmVbNFqBacBi17TZGlcGQ56DavQTGHAOS5NhJ3No_C7HVjtpHvRLW8oF1gbXrrJaOu1OPYgnjSy07zT6eH1bATxgC7Lwc6FzwPBcg9VgFOCstdrc4eYe8Hg2n5x5hApc-1tQarWPdnJZODj46T10e3F-M74KprPLyXg0DRRPEh6IWEoSAaOLoQiViiMpOWWMc0YAwpiJJMkUYXHEWMYZCxdkyGKZUB7FoSAi5z10vPHWtnpswTVpqZ2CopAGqtalbBh6CWeUePRkgypbOWchT2urS2nXKSXpVxCpDyL9DsKzRz_adlFC9kf-ft4Dgw2w0gWs_zel12fzjfIT7ZmUsw</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Hansel, K.</creator><creator>Zangrilli, A.</creator><creator>Bianchi, L.</creator><creator>Peris, K.</creator><creator>Chiricozzi, A.</creator><creator>Offidani, A.</creator><creator>Diotallevi, F.</creator><creator>Fargnoli, M.C.</creator><creator>Esposito, M.</creator><creator>Amerio, P.</creator><creator>Gualdi, G.</creator><creator>Bianchi, L.</creator><creator>Stingeni, L.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7919-8141</orcidid><orcidid>https://orcid.org/0000-0002-4773-6993</orcidid><orcidid>https://orcid.org/0000-0002-6674-4278</orcidid><orcidid>https://orcid.org/0000-0002-7249-2556</orcidid><orcidid>https://orcid.org/0000-0003-2274-1742</orcidid><orcidid>https://orcid.org/0000-0003-1957-6600</orcidid><orcidid>https://orcid.org/0000-0002-1640-6609</orcidid><orcidid>https://orcid.org/0000-0002-6739-0387</orcidid></search><sort><creationdate>202103</creationdate><title>A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic</title><author>Hansel, K. ; Zangrilli, A. ; Bianchi, L. ; Peris, K. ; Chiricozzi, A. ; Offidani, A. ; Diotallevi, F. ; Fargnoli, M.C. ; Esposito, M. ; Amerio, P. ; Gualdi, G. ; Bianchi, L. ; Stingeni, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-97aa06e21b495cc76aa31223320ee572988dc027622d3225b0427a813675909f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>COVID-19 - epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Italy - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>Psoriasis - drug therapy</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hansel, K.</creatorcontrib><creatorcontrib>Zangrilli, A.</creatorcontrib><creatorcontrib>Bianchi, L.</creatorcontrib><creatorcontrib>Peris, K.</creatorcontrib><creatorcontrib>Chiricozzi, A.</creatorcontrib><creatorcontrib>Offidani, A.</creatorcontrib><creatorcontrib>Diotallevi, F.</creatorcontrib><creatorcontrib>Fargnoli, M.C.</creatorcontrib><creatorcontrib>Esposito, M.</creatorcontrib><creatorcontrib>Amerio, P.</creatorcontrib><creatorcontrib>Gualdi, G.</creatorcontrib><creatorcontrib>Bianchi, L.</creatorcontrib><creatorcontrib>Stingeni, L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hansel, K.</au><au>Zangrilli, A.</au><au>Bianchi, L.</au><au>Peris, K.</au><au>Chiricozzi, A.</au><au>Offidani, A.</au><au>Diotallevi, F.</au><au>Fargnoli, M.C.</au><au>Esposito, M.</au><au>Amerio, P.</au><au>Gualdi, G.</au><au>Bianchi, L.</au><au>Stingeni, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2021-03</date><risdate>2021</risdate><volume>35</volume><issue>3</issue><spage>e169</spage><epage>e170</epage><pages>e169-e170</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><cop>England</cop><pmid>33080112</pmid><doi>10.1111/jdv.17003</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-7919-8141</orcidid><orcidid>https://orcid.org/0000-0002-4773-6993</orcidid><orcidid>https://orcid.org/0000-0002-6674-4278</orcidid><orcidid>https://orcid.org/0000-0002-7249-2556</orcidid><orcidid>https://orcid.org/0000-0003-2274-1742</orcidid><orcidid>https://orcid.org/0000-0003-1957-6600</orcidid><orcidid>https://orcid.org/0000-0002-1640-6609</orcidid><orcidid>https://orcid.org/0000-0002-6739-0387</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2021-03, Vol.35 (3), p.e169-e170 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2452983210 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Antibodies, Monoclonal - therapeutic use COVID-19 - epidemiology Female Humans Italy - epidemiology Male Middle Aged Pandemics Psoriasis - drug therapy SARS-CoV-2 |
| title | A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T13%3A20%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20multicenter%20study%20on%20effectiveness%20and%20safety%20of%20risankizumab%20in%20psoriasis:%20an%20Italian%2016%E2%80%90week%20real%E2%80%90life%20experience%20during%20the%20COVID%E2%80%9019%20pandemic&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Hansel,%20K.&rft.date=2021-03&rft.volume=35&rft.issue=3&rft.spage=e169&rft.epage=e170&rft.pages=e169-e170&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.17003&rft_dat=%3Cproquest_cross%3E2452983210%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452983210&rft_id=info:pmid/33080112&rfr_iscdi=true |